mRNA-1273 (Moderna COVID-19 vaccine)

BIOLOGICAL2 trials

Sponsors

University of California, Los Angeles, Tor Biering-Sørensen

Conditions

COVID-19ImmunosuppressionLung Transplant RecipientSARS-CoV-2

Phase 1

High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients

TerminatedNCT05280158

University of California, Los AngelesImmunosuppression, Lung Transplant Recipient, SARS-CoV-2

Start: 2022-03-10End: 2023-02-27Updated: 2025-03-26

Phase 4

Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

Active, not recruitingNCT07279766

Tor Biering-SørensenCOVID-19

Start: 2025-12-11End: 2026-08-01Target: 285000Updated: 2026-03-16

Related Papers

A Phase I/II Randomized Trial of Higher Dose mRNA-1273 Boosters in Lung Transplant Recipients

OBM Transplantation2024-11-20